How many drugs treat Depression Treatment Adjunct?

Drug Landscape tracks 7 marketed treatments for Depression Treatment Adjunct (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/depression-treatment-adjunct.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Depression Treatment Adjunct — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Depression Treatment Adjunct (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Depression Treatment Adjunct, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Abilify	aripiprazole	Generic (originally Otsuka/BMS)	Third-generation antipsychotic (D2 partial agonist)	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6	2002-11-15
Seroquel	quetiapine	AstraZeneca		Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Zyprexa	olanzapine	Eli Lilly	Atypical Antipsychotic [EPC]	Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Abilify	Abilify	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.		5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6
Seroquel	Seroquel	University of Pittsburgh		Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Quetiapin	Quetiapin	Sykehuset Innlandet HF		Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A
Zyprexa	Zyprexa	Washington University School of Medicine		Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 1 drug in Depression Treatment Adjunct
Eli Lilly · 1 drug in Depression Treatment Adjunct
Generic (originally Otsuka/BMS) · 1 drug in Depression Treatment Adjunct
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in Depression Treatment Adjunct
Sykehuset Innlandet HF · 1 drug in Depression Treatment Adjunct
University of Pittsburgh · 1 drug in Depression Treatment Adjunct
Washington University School of Medicine · 1 drug in Depression Treatment Adjunct

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Depression Treatment Adjunct:

Cite this brief

Drug Landscape (2026). Depression Treatment Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/depression-treatment-adjunct. Accessed 2026-06-11.

Depression Treatment Adjunct full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing